United Therapeutics (UTHR) CFO Edgemond sold 10,000 shares for $5.46M at an average $546.28 under a 10b5-1 plan
Insider transactions reported
James Edgemond (CFO and Treasurer at United Therapeutics Corporation, UTHR) reported that they sold 10,000 shares for $5.46M at an average $546.28, and acquired 10,000 shares at $117.76 on Jun 4, 2026. After these transactions the filing shows 18,876 shares held directly.
- Reporting person
- Edgemond James
- Role
- CFO AND TREASURER
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +10,000 | $117.76 | $1.18M | 28,876 direct |
| Jun 4, 2026 | Open-market sale (S) | Common Stock1, 2, 3, ... | -10,000 | avg $546.28 | $5.46M | 18,876 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Exercise or conversion of a derivative (M) | Stock OptionOn 10,000 Common Stock1 | -10,000 | - | - | 30,000 direct |
Holdings before and after
- Stock Option: 40,000 to 30,000 direct
Footnotes from the filing
- 1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- 2. This transaction was executed in multiple trades at prices ranging from $539.29 to $540.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Edgemond report in this UTHR Form 4?
James Edgemond (CFO and Treasurer at United Therapeutics Corporation, UTHR) reported that they sold 10,000 shares for $5.46M at an average $546.28, and acquired 10,000 shares at $117.76 on Jun 4, 2026. After these transactions the filing shows 18,876 shares held directly.
How many UTHR shares does Edgemond hold after this filing?
The filing shows 18,876 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this UTHR insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for UTHR
Across the 28 sessions after earlier UTHR headlines, the stock closed higher 15 times and lower 13 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | UTHR | SPY |
|---|---|---|---|
| May 27, 2026 | United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference | -1.3% | -0.0% |
| May 19, 2026 | United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 | -0.0% | -0.7% |
| May 18, 2026 | United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026and 1 other headline that session | -0.3% | -0.1% |
| May 13, 2026 | Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease | -0.4% | +0.6% |
| May 12, 2026 | United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference | +2.1% | -0.2% |
| May 11, 2026 | United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026 | +0.9% | +0.2% |
Earlier insider filings at UTHR
- Jun 4, 2026EVP & GENERAL COUNSEL Mahon Paul A exercised 8,300 shares at a strike of $146.03 and sold $4,540,642 worth of shares (8,300 units at $547.07) as part of a pre-agreed trading plan (SEC Form 4)
- Jun 4, 2026Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $5,202,271 worth of shares (9,500 units at $547.61) as part of a pre-agreed trading plan (SEC Form 4)
- Jun 3, 2026Chairperson & CEO Rothblatt Martine A sold $5,114,742 worth of shares (9,500 units at $538.39) as part of a pre-agreed trading plan and exercised 9,500 shares at a strike of $146.03 (SEC Form 4)
- Jun 2, 2026Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $5,205,105 worth of shares (9,500 units at $547.91) as part of a pre-agreed trading plan (SEC Form 4)
- Jun 2, 2026CFO AND TREASURER Edgemond James exercised 10,000 shares at a strike of $117.76 and sold $5,478,663 worth of shares (10,000 units at $547.87) as part of a pre-agreed trading plan (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1999
Follow UTHR and get a push notification the moment its next story breaks.